SequelSEC

Orchestra BioMed Holdings, Inc. OBIO

Surgical & Medical Instruments & Apparatus · CIK 0001814114 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$88.00K
Fiscal year ended 2026-06-30
Operating income
-$22.36M
Fiscal year ended 2026-06-30
Free cash flow
-$19.59M
Fiscal year ended 2026-06-30

Orchestra BioMed Holdings, Inc. (OBIO) reported revenue of $88.00K and net income of -$23.76M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Orchestra BioMed Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Orchestra BioMed Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$88.00K$110.00K$30.92M$861.00K$836.00K$868.00K$253.00K$987.00K$778.00K$620.00K
Cost of revenue$25.00K$32.00K$51.00K$49.00K$46.00K$44.00K$58.00K$68.00K$44.00K$34.00K
Gross profit$63.00K$78.00K$30.87M$812.00K$790.00K$824.00K$195.00K$919.00K$734.00K$586.00K
Operating income-$22.36M-$22.08M$6.75M-$20.31M-$19.33M-$18.92M-$16.68M-$16.34M-$16.86M-$14.42M
Net income-$23.76M-$20.69M$6.24M-$20.83M-$19.36M-$18.76M-$16.16M-$15.43M-$15.98M-$13.46M
Research & development$16.59M$15.78M$16.82M$14.03M$13.85M$13.48M$10.97M$11.60M$11.13M$9.11M
Weighted-average diluted sharesshares 63.81Mshares 62.72MUnavailableshares 52.19Mshares 38.39Mshares 38.24MUnavailableshares 37.62Mshares 35.80Mshares 35.78M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.38$-0.33Unavailable$-0.40$-0.50$-0.49Unavailable$-0.41$-0.45$-0.38
Selling, general & administrative$5.83M$6.37M$7.29M$7.10M$6.26M$6.26M$5.90M$5.67M$6.47M$5.90M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Orchestra BioMed Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$20.47M$28.37M$34.69M$42.01M$18.75M$18.35M$22.26M$25.60M$23.71M$23.32M
Total assets$115.70M$100.66M$114.86M$104.81M$42.82M$59.05M$76.17M$75.32M$72.38M$82.63M
Current assets$111.24M$96.21M$107.91M$97.77M$35.88M$51.90M$69.17M$68.55M$66.48M$76.43M
Total liabilities$86.28M$49.69M$51.48M$61.07M$42.53M$42.19M$43.22M$29.10M$28.26M$25.44M
Current liabilities$13.47M$13.69M$16.74M$20.66M$17.06M$15.49M$16.21M$16.22M$14.50M$10.42M
Total equity incl. NCI$19.32M$41.19M$53.57M$43.74M$295.00K$16.86M$32.96M$46.22M$44.12M$57.19M
Temporary (mezzanine) equity$10.10M$9.77M$9.81MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$250.00K$277.00K$310.00K$365.00K$185.00K$135.00K$173.00K$234.00K$70.00K$115.00K
Accounts receivable$51.00K$84.00K$95.00K$52.00K$83.00K$89.00K$92.00K$115.00K$80.00K$67.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$15.00M$15.00M$15.00M$15.00M$15.00M$15.00MUnavailableUnavailableUnavailable
Accounts payable$6.13M$6.31M$6.10M$8.47M$5.31M$5.56M$5.13M$4.72M$6.27M$3.35M

Cash flow

Orchestra BioMed Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$19.33M-$22.17M-$2.27M-$14.55M-$15.53M-$16.62M-$13.54M-$13.70M-$10.21M-$13.11M
Capital expenditures$254.00K$184.00K$33.00K$310.00K$34.00K$112.00K$106.00K$68.00K$107.00K$8.00K
Investing cash flow-$23.31M$10.32M-$17.71M-$38.58M$16.36M$13.00M-$3.75M$557.00K$10.42M$5.86M
Financing cash flow$34.75M$5.53M$12.66M$76.40M-$428.00K-$296.00K$13.95M$15.04M$171.00K$18.00K
Net change in cash-$7.90M-$6.32M-$7.32M$23.26M$401.00K-$3.91M-$3.34M$1.89M$389.00K-$7.24M
Stock-based compensation$2.50M$2.85M$2.75M$3.01M$3.25M$2.96M$2.90M$2.36M$2.76M$2.59M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$96.00K$90.00K$82.00K$81.00K$81.00K$83.00K$84.00K$76.00K$74.00K$74.00K

Derived

Orchestra BioMed Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$19.59M-$22.35M-$2.30M-$14.86M-$15.56M-$16.73M-$13.64M-$13.77M-$10.31M-$13.12M
Gross margin71.6%70.9%99.8%94.3%94.5%94.9%77.1%93.1%94.3%94.5%
Operating margin-25404.5%-20069.1%21.8%-2359.2%-2311.8%-2179.8%-6591.7%-1655.7%-2167.0%-2326.3%
FCF margin-22256.8%-20320.0%-7.4%-1725.9%-1861.4%-1927.2%-5392.9%-1394.9%-1325.6%-2116.5%
SBC / revenue2846.6%2591.8%8.9%349.9%388.8%341.6%1147.0%239.5%354.9%417.4%
Current ratio8.26x7.03x6.45x4.73x2.10x3.35x4.27x4.23x4.58x7.34x
Revenue YoY growth-89.5%-87.3%12120.2%-12.8%7.5%40.0%-3.4%135.6%-15.0%-46.7%
Net margin-26994.3%Unavailable20.2%-2419.0%-2316.1%Unavailable-6385.4%-1562.9%UnavailableUnavailable
R&D / revenue18852.3%14346.4%54.4%1629.2%1657.1%1553.2%4336.4%1174.8%1430.1%1469.7%
CapEx / revenue288.6%167.3%0.1%36.0%4.1%12.9%41.9%6.9%13.8%1.3%
Long-term debt / equityUnavailableUnavailableUnavailable0.34xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2022-12-31

Difference 67676498 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2022-09-30

Difference 67495954 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.